Leading research for
ME/CFS and Long-Covid

First-in-kind Mouse Models
• New Mechanisms
• Emerging Treatment Pathways

First in ME/CFS Research

Mouse Model Study

Autophagy Studies

Cellular Treatable Pathways

Spinal Fluid Studies

Connecting the dots: ME/CFS + Long-Covid

We served our community in the crisis and connected the research dots between ME long-haulers and COVID long-haulers. After all, most ME/CFS patients developed chronic disease following an infection.

The Simmaron Difference

Uniting patients, doctors, and scientists in a quest for breakthroughs in ME/CFS & neuroimmune disease. Simmaron has a 40 year-old biobank, clinical expertise of Dr. Daniel Peterson, and excellence in collaborations. We are uniquely aimed at discovering diagnostics and treatments for ME/CFS.

People working in the lab

Simmaron’s New Lab

Simmaron is starting animal research for drug discovery and molecular target identification. Diseases with mouse models have active drug pipelines, so our researchers are developing the first mouse models for ME/CFS.

Our Core Accomplishments

Over 22 peer reviewed publications on ME/CFS immunology, subsets and treatments.

Transformational collaborations with CDC, NIH, Columbia University, Cornell University, Stanford, Griffith University Australia and University of Wisconsin Milwaukee.

$3.5 million of funded research to date.